Welcome to our dedicated page for Senti Biosciences Holdings news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Biosciences Holdings stock.
Senti Biosciences Holdings, Inc. (SNTI) operates through Senti Bio as a clinical-stage biotechnology company developing cell and gene therapies built on a proprietary Gene Circuit synthetic biology platform. The company’s Gene Circuits are designed to program cells to sense, compute and respond to cellular environments, with applications intended to kill cancer cells, spare healthy cells, improve tissue specificity and allow post-administration control.
Recurring SNTI news centers on the Logic-Gated SENTI-202 program, an off-the-shelf CAR NK cell therapy targeting CD33 and/or FLT3 while sparing EMCN-expressing healthy cells in relapsed or refractory acute myeloid leukemia. Company updates also cover clinical and translational data presentations, peer-reviewed research on NOT-gated CAR circuits in T cells and NK cells, FDA designations for SENTI-202, financial results, conference appearances, and partnership discussions tied to the Gene Circuit platform.
Senti Biosciences, Inc. (SNTI) reported a significant milestone with the selection of a lead development candidate from its SENTI-202 program, targeting acute myeloid leukemia (AML), with an IND filing expected in 2023. As of June 30, 2022, the company holds $139.8 million in cash, sufficient to support operations into 2024. However, R&D expenses increased to $9.2 million, and G&A expenses surged to $13.9 million, contributing to a net loss of $11.6 million for the second quarter, compared to $5.2 million and $4.6 million for the same quarter in 2021, respectively.